U.S. Department of Health and Human Services
Yaron Rotman
 

 Contact Info

 
Tel: +1 301 451 6553
Email: rotmanyaron@mail.nih.gov
 

 Training and Experience

 
M.D., Hebrew University Hadassah Medical School, 2000

M.Sc., Hebrew University Hadassah Medical School, 2000

Clinical Research Fellow, Liver Diseases Branch, NIDDK, 2006-2009

Gastroenterology and Hepatology Fellowship, Rabin Medical Center, 2003-2006

Internal Medicine Residency, Rabin Medical Center, 2000-2003
 

 Related Links

 

    Yaron Rotman, M.D., M.Sc.

    Assistant Clinical Investigator, Liver Diseases Branch, Office of the Chief
    Specialties: Cell Biology/Cell Signaling, Molecular Biology/Biochemistry, Clinical Research, Genetics/Genomics

    Research Summary

    Research Goal

    My ultimate goal is to increase understanding of the pathophysiology of fatty liver disease to allow for development of better treatment options.

    Current Research

    Non-alcoholic fatty liver disease (NAFLD) is the most common liver disorder in the western world and is closely associated with metabolic syndrome, insulin resistance, and obesity.  My main interest is in understanding the disease pathophysiology and through it, normal liver physiology.  My studies focus on understanding the genetic aspects of fatty liver disease, its pathogenesis, the mechanisms of action of various treatment options, and the prediction of response to treatment.​

    Applying our Research

    Non-alcoholic fatty liver disease is an extremely common disorder (affecting 30 percent of Americans) but currently has no approved therapy.  Better understanding of the mechanisms of disease may allow for identification of druggable targets, better selection of patients for treatment, and early prediction of treatment response, with the overall effect of preventing death and suffering associated with the disease.

    Need for Further Study

    We need a better understanding of the mechanisms that cause some individuals to accumulate fat in the liver during caloric excess, while others are protected.  Similarly, it is unclear why some individuals will develop liver injury and progressive disease after accumulating fat in their liver, while others maintain a relatively benign course.  Finally, better treatment options are needed.